Synonym
Meturedepa; AB 132; AB-132; AB132
IUPAC/Chemical Name
(Bis(2,2-dimethyl-1-aziridinyl)phosphinyl)carbamic acid, ethyl ester
InChi Key
QTFKTBRIGWJQQL-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H22N3O3P/c1-6-17-9(15)12-18(16,13-7-10(13,2)3)14-8-11(14,4)5/h6-8H2,1-5H3,(H,12,15,16)
SMILES Code
O=C(OCC)NP(N1C(C)(C)C1)(N2C(C)(C)C2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
275.89
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Moore GE, Bross ID, Ausman R, Nadler S, Jones R Jr, Slack N, Rimm AA. Effects of meturedepa (NSC-51325) in 233 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep. 1968 Oct;52(6):667-73. PubMed PMID: 4895430.
2: Ambrus JL, Ambrus CM, Bardos TJ, Chmielewicz ZF. Radiation sensitizing agents in clinical radiation and chemotherapy. J Med. 1980;11(1):29-38. PubMed PMID: 6156977.
3: WATNE AL, MOORE GE, ROSS CA, AMBRUS JL. Clinical experience with AB-132. Cancer Chemother Rep. 1962 Feb;16:421-3. PubMed PMID: 14005262.
4: BACK N, BARDOS TJ, CHMIELEWICZ ZF, ACHTER E, MUNSON AE. STUDIES ON THE MECHANISM OF ACTION OF CYCLOPHOSPHAMIDE AND AB-132 WITH THE AID OF RADIOPROTECTIVE AGENTS. Life Sci (1962). 1964 Aug;3:803-8. PubMed PMID: 14201688.
5: MECHL Z, KOLAR V, KONECNY M. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS. Neoplasma. 1964;11:491-8. PubMed PMID: 14220338.
6: STUTZMAN L, RAZIS DV, SOKAL JE, AMBRUS JL, ROSS CA. Clinical experience with a new alkylating agent AB-132, in the treatment of lymphomas and leukemias. Cancer Chemother Rep. 1962 May;18:31-5. PubMed PMID: 13918060.
7: REGELSON W, PIERUCCI O. THE EFFECT OF RADIATION ON SPLENOMEGALY INDUCED BY THE FRIEND LEUKEMIA VIRUS AND ITS MODIFICATION BY ETHY-N-BIS(2,2-DIMETHYL-ETHYLAMIDINOPHOSPHORO)-CARBAMATE (AB-132), ACTINOMYCIN D, AND AET. Radiat Res. 1964 Jun;22:368-82. PubMed PMID: 14168897.
8: WANG RI, ROSS CA. Prolonged apnea following succinylcholine in cancer patients receiving AB-132. Anesthesiology. 1963 May-Jun;24:363-7. PubMed PMID: 13998795.
9: VELASCO HA, ROSS CA, WEBSTER JH, SOKAL JE, STUTZMAN L, AMBRUS JL. COMBINED USE OF AB-132 (METUREDEPA, TURLOC) AND X-IRRADIATION IN THE MANAGEMENT OF ADVANCED BRONCHOGENIC CARCINOMA. Cancer. 1964 Jul;17:841-9. PubMed PMID: 14184043.
